AlenCiken

XPro1595 Decreases Neuroinflammation in Patients with Alzheimer’

NASDAQ:INMB   INmune Bio Inc.
INmune Bio, Inc. Announces Interim Phase Ib Data Demonstrating That XPro1595 Decreases Neuroinflammation in Patients with Alzheimer’s Disease

XPro1595 reduces neuroinflammation by 40.6% in a brain fiber pathway important for learning and memory

Interim results from a Phase Ib clinical trial show that treatment with XPro1595 decreases white matter free water, a biomarker of neuroinflammation measured by MRI

The preliminary results from INmune Bio’s Phase Ib study add to the growing enthusiasm for tackling neuroinflammation in the treatment of Alzheimer’s disease.

www.globenewswire.co...eimer-s-Disease.html

免責事項

これらの情報および投稿は、TradingViewが提供または保証する金融、投資、取引、またはその他の種類のアドバイスや推奨を意図したものではなく、またそのようなものでもありません。詳しくは利用規約をご覧ください。